Expanding the Spectrum of HER2 Positivity for Breast Cancer Care: Implications of HER2-Low Status

Review the latest evidence on HER2 testing, clinical implications of HER2-low status in advanced breast cancer, and mastering the safety profile of antibody-drug conjugates, including current guidelines and expert’s recommendations.

Nadia Harbeck, MD, PhD Komal Jhaveri, MD Heather McArthur, MD, MPH Released: December 8, 2022

Download this short summary slideset of key takeaways from a live satellite symposium on new developments in precision care for advanced HER2-low breast cancer.

Nadia Harbeck, MD, PhD Komal Jhaveri, MD Heather McArthur, MD, MPH Released: December 16, 2022

In this on-demand webcast from a live symposium, Nadia Harbeck, MD, PhD; Komal Jhaveri, MD; and Heather McArthur, MD, MPH, discuss current guidelines for the assessment of HER2 status in advanced breast cancer, including expanding the spectrum of HER2 positivity and mastering the use and safety of novel antibody–drug conjugates.

Nadia Harbeck, MD, PhD Komal Jhaveri, MD Heather McArthur, MD, MPH Physicians: maximum of 1.5 AMA PRA Category 1 Credits™ Released: January 19, 2023 Expired: January 18, 2024